Next Article in Journal
Cognition in Children with Arachnoid Cysts
Previous Article in Journal
High Risk of Sustained Ventricular Arrhythmia Recurrence After Acute Myocarditis
Open AccessArticle

Pentraxin 3 (PTX3): A Molecular Marker of Endothelial Dysfunction in Chronic Migraine

1
Headache Unit, Department of Neurology, University Clinical Hospital, Universidade de Santiago de Compostela, 15706 Santiago de Compostela, Spain
2
UCL Eastman Dental Institute and NIHR UCLH Biomedical Research Centre, University College London, London WC1X 8LD, UK
3
Medical-Surgical Dentistry (OMEQUI) Research Group, Health Research Institute of Santiago de Compostela, 15782 Santiago de Compostela, Spain
4
Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain
*
Author to whom correspondence should be addressed.
These two authors contributed equally to the manuscript.
J. Clin. Med. 2020, 9(3), 849; https://doi.org/10.3390/jcm9030849
Received: 20 February 2020 / Revised: 9 March 2020 / Accepted: 18 March 2020 / Published: 20 March 2020
(This article belongs to the Section Clinical Neurology)
Even though endothelial dysfunction is known to play a role in migraine pathophysiology, studies regarding levels of endothelial biomarkers in migraine have controversial results. Our aim was to evaluate the role of pentraxin 3 (PTX3) and soluble tumour necrosis factor-like weak inducer of apoptosis (sTWEAK) as potential biomarkers of endothelial dysfunction in chronic migraine (CM). We performed a case-control study including 102 CM patients and 28 control subjects and measured serum levels of markers of endothelial dysfunction (PTX3 and sTWEAK) and inflammation [high-sensitivity C-reactive protein (hs-CRP)] as well as brachial artery flow-mediated dilation (FMD) during interictal periods. Interictal serum levels of PTX3 and sTWEAK were higher in CM patients than in controls (1350.6 ± 54.8 versus 476.1 ± 49.4 pg/mL, p < 0.001 and 255.7 ± 21.1 versus 26.4 ± 2.6 pg/mL, p < 0.0001; respectively). FMD was diminished in CM patients compared to controls (9.6 ± 0.6 versus 15.2 ± 0.9%, p < 0.001). Both PTX3 and sTWEAK were negatively correlated with FMD (r = −0.508, p < 0.001 and r = −0.188, p = 0.033; respectively). After adjustment of confounders, PTX3 remained significantly correlated to FMD (r = −0.250, p = 0.013). Diagnosis of CM was 68.4 times more likely in an individual with levels of PTX3 ≥ 832.5 pg/mL, suggesting that PTX3 could be a novel biomarker of endothelial dysfunction in CM. View Full-Text
Keywords: PTX3; sTWEAK; endothelial dysfunction; chronic migraine; FMD PTX3; sTWEAK; endothelial dysfunction; chronic migraine; FMD
Show Figures

Figure 1

MDPI and ACS Style

Domínguez-Vivero, C.; Leira, Y.; López-Ferreiro, A.; Saavedra, M.; Rodríguez-Osorio, X.; Sobrino, T.; Campos, F.; Castillo, J.; Leira, R. Pentraxin 3 (PTX3): A Molecular Marker of Endothelial Dysfunction in Chronic Migraine. J. Clin. Med. 2020, 9, 849.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop